Insider Selling: Moderna, Inc. (NASDAQ:MRNA) CEO Sells 40,000 Shares of Stock

Moderna, Inc. (NASDAQ:MRNAGet Rating) CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $192.94, for a total transaction of $7,717,600.00. Following the transaction, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $1,044,180,861.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stephane Bancel also recently made the following trade(s):

  • On Thursday, July 28th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $156.73, for a total value of $6,269,200.00.
  • On Thursday, July 21st, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $168.11, for a total value of $6,724,400.00.
  • On Wednesday, July 13th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $172.69, for a total value of $6,907,600.00.
  • On Thursday, July 7th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $171.00, for a total value of $6,840,000.00.
  • On Thursday, June 30th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $143.21, for a total value of $5,728,400.00.
  • On Wednesday, June 22nd, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $136.58, for a total value of $5,463,200.00.
  • On Thursday, May 26th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $133.89, for a total value of $5,355,600.00.
  • On Thursday, May 19th, Stephane Bancel sold 10,000 shares of Moderna stock. The stock was sold at an average price of $140.96, for a total value of $1,409,600.00.
  • On Wednesday, May 11th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $127.13, for a total value of $1,144,170.00.

Moderna Price Performance

NASDAQ:MRNA traded down $7.34 on Friday, reaching $186.84. 5,422,925 shares of the company’s stock traded hands, compared to its average volume of 6,847,177. The company has a quick ratio of 1.56, a current ratio of 1.99 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $151.55 and a 200-day simple moving average of $152.84. The firm has a market cap of $74.32 billion, a PE ratio of 5.58, a P/E/G ratio of 1.05 and a beta of 1.61. Moderna, Inc. has a 12 month low of $115.61 and a 12 month high of $497.49.

Moderna (NASDAQ:MRNAGet Rating) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $5.24 EPS for the quarter, beating analysts’ consensus estimates of $4.73 by $0.51. The business had revenue of $4.73 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the firm earned $6.46 earnings per share. Equities research analysts forecast that Moderna, Inc. will post 27.29 earnings per share for the current year.

Analyst Ratings Changes

MRNA has been the topic of several analyst reports. SVB Leerink lifted their target price on Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a research report on Monday. Piper Sandler lowered their target price on Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 17th. Finally, Morgan Stanley lowered their target price on Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a research report on Thursday. One analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $226.92.

Institutional Investors Weigh In On Moderna

Several large investors have recently made changes to their positions in the company. Reynders McVeigh Capital Management LLC increased its holdings in shares of Moderna by 2.5% in the second quarter. Reynders McVeigh Capital Management LLC now owns 14,449 shares of the company’s stock worth $2,064,000 after purchasing an additional 351 shares during the last quarter. Pinebridge Investments L.P. increased its stake in Moderna by 59.8% during the second quarter. Pinebridge Investments L.P. now owns 54,863 shares of the company’s stock worth $7,837,000 after acquiring an additional 20,533 shares during the last quarter. Financial Gravity Asset Management Inc. raised its position in Moderna by 108.3% during the second quarter. Financial Gravity Asset Management Inc. now owns 5,134 shares of the company’s stock valued at $1,061,000 after purchasing an additional 2,669 shares during the period. Abundance Wealth Counselors lifted its stake in shares of Moderna by 15.8% in the 2nd quarter. Abundance Wealth Counselors now owns 4,496 shares of the company’s stock valued at $642,000 after purchasing an additional 612 shares during the last quarter. Finally, Illinois Municipal Retirement Fund boosted its holdings in shares of Moderna by 518.3% in the 2nd quarter. Illinois Municipal Retirement Fund now owns 45,019 shares of the company’s stock worth $6,431,000 after purchasing an additional 37,738 shares during the period. 61.20% of the stock is owned by institutional investors.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.